ADRB2 and prostate carcinoma: The β2-adrenergic receptor (ADRB2) and its downstream effectors cyclic AMP (cAMP) and cAMP-dependent protein kinase A (PKA) have been implicated in prostate cancer progression and AR signaling [11].